Risultati della ricerca - Seock‐Ah Im
- Mostra 1 - 20 risultati su 142
- Vai alla pagina seguente
-
1
PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation di Ahrum Min, Seock Ah Im
Pubblicazione 2020Revisão -
2
HLA‐B27 association of autoimmune encephalitis induced by PD‐L1 inhibitor di Hyeyeon Chang, Yong‐Won Shin, Bhumsuk Keam, Miso Kim, Seock‐Ah Im, Soon‐Tae Lee
Pubblicazione 2020Artigo -
3
Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive, First-Line Metastatic Breast Cancer di José Baselga, Javier Cortés, Seock‐Ah Im, Emma Clark, Graham Ross, Astrid Kiermaier, Sandra M. Swain
Pubblicazione 2014Artigo -
4
-
5
-
6
-
7
-
8
Antibiotic use during the last days of life in cancer patients di Dong Yoon Oh, J. Kim, Dong‐Wan Kim, Seock‐Ah Im, T.Y. KIM, D. S. Heo, Y-J. Bang, N.K. KIM
Pubblicazione 2006Artigo -
9
Safety Profile of Pertuzumab With Trastuzumab and Docetaxel in Patients From Asia With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Results From the... di Sandra M. Swain, Young‐Hyuck Im, Seock‐Ah Im, Valorie F. Chan, David Miles, Adam Knott, Emma Clark, Graham Ross, José Baselga
Pubblicazione 2014Artigo -
10
Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index di Younak Choi, Do‐Youn Oh, Tae‐Yong Kim, Kyung-Hun Lee, Sae‐Won Han, Seock‐Ah Im, Tae‐You Kim, Yung‐Jue Bang
Pubblicazione 2015Artigo -
11
-
12
-
13
Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer:... di Johannes Ettl, Seock-Ah Im, Jungsil Ro, Norikazu Masuda, Marco Colleoni, Patrick Schnell, Eustratios Bananis, Dongrui R. Lu, Massimo Cristofanilli, Hope S. Rugo, Richard S. Finn
Pubblicazione 2020Artigo -
14
Olaparib efficacy in patients with germline <scp>BRCA</scp>‐mutated, <scp>HER2</scp>‐negative metastatic breast cancer: Subgroup analyses from the phase <scp>III OlympiAD</scp> tri... di Elżbieta Senkus, Suzette Delaloge, Susan M. Domchek, Pierfranco Conté, Seock‐Ah Im, Binghe Xu, Anne Armstrong, Norikazu Masuda, Anitra Fielding, Mark E. Robson, Nadine Tung
Pubblicazione 2023Artigo -
15
-
16
Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy is useful to predict a more accurate prognosis of advanced biliary tract... di Kyoung-Min Cho, Hyunkyung Park, Do‐Youn Oh, Tae‐Yong Kim, Kyung-Hun Lee, Sae‐Won Han, Seock‐Ah Im, Tae‐You Kim, Yung‐Jue Bang
Pubblicazione 2016Artigo -
17
-
18
Antitumor effect of a WEE1 inhibitor and potentiation of olaparib sensitivity by DNA damage response modulation in triple-negative breast cancer di Dong-Hyeon Ha, Ahrum Min, Seongyeong Kim, Hyemin Jang, So Hyeon Kim, Hee Jun Kim, Han Suk Ryu, Ja‐Lok Ku, Kyung-Hun Lee, Seock‐Ah Im
Pubblicazione 2020Artigo -
19
The impact of race and ethnicity in breast cancer—disparities and implications for precision oncology di Kelly A. Hirko, Gabrielle B. Rocque, Erica Reasor, Ammanuel Taye, Alex Daly, Ramsey Cutress, Ellen Copson, Dae‐Won Lee, Kyung-Hun Lee, Seock‐Ah Im, Yeon Hee Park
Pubblicazione 2022Artigo -
20
<i>ERCC1</i> and <i>ERCC2</i> Polymorphisms Predict Clinical Outcomes of Oxaliplatin-Based Chemotherapies in Gastric and Colorectal Cancer: A Systemic Review and Meta-analysis di Ming Yin, Jingrong Yan, Eva Martinez‐Balibrea, Francesco Graziano, Heinz‐Josef Lenz, Hyo-Jin Kim, Jacques Robert, Seock‐Ah Im, Wei-Shu Wang, Marie-Christine Etienne-Grimaldi, Qingyi Wei
Pubblicazione 2011Revisão
Strumenti per la ricerca:
Soggetti correlati
Cancer
Medicine
Internal medicine
Oncology
Breast cancer
Chemotherapy
Metastatic breast cancer
Biology
Confidence interval
Hazard ratio
Pathology
Trastuzumab
Cancer research
Biochemistry
Gastroenterology
Clinical trial
Clinical endpoint
Gene
Genetics
Gynecology
Tamoxifen
Alternative medicine
Adverse effect
Placebo
Estrogen receptor
Immunotherapy
Palbociclib
Fulvestrant
Triple-negative breast cancer
Environmental health